NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
from PR Newswire: https://ift.tt/2RQS8BZ
No comments:
Post a Comment